Home » Stocks » NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc. (NGM)

Stock Price: $19.13 USD -0.16 (-0.83%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.30B
Revenue (ttm) 102.36M
Net Income (ttm) -53.64M
Shares Out 68.14M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $19.13
Previous Close $19.29
Change ($) -0.16
Change (%) -0.83%
Day's Open 19.29
Day's Range 18.99 - 19.61
Day's Volume 174,666
52-Week Range 8.81 - 23.95

More Stats

Market Cap 1.30B
Enterprise Value 973.21M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 68.14M
Float 19.58M
EPS (basic) -0.83
EPS (diluted) -0.82
FCF / Share -0.75
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.71M
Short Ratio 14.30
Short % of Float 15.01%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 12.74
PB Ratio 4.24
Revenue 102.36M
Operating Income -163.02M
Net Income -53.64M
Free Cash Flow -50.47M
Net Cash 330.34M
Net Cash / Share 4.85
Gross Margin 40.34%
Operating Margin -159.27%
Profit Margin n/a
FCF Margin -49.31%
ROA -12.80%
ROE -21.68%
ROIC -70.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(62.05% upside)
Current: 19.13
Target: 31.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-153-113-94.57
Net Income-42.80-0.49-14.16
Shares Outstanding50.306.385.96
Earnings Per Share-0.85-0.08-2.37
Operating Cash Flow-41.17-7.60-17.41
Capital Expenditures-3.49-5.84-6.42
Free Cash Flow-44.66-13.44-23.84
Cash & Equivalents346209176
Net Cash / Debt346209176
Book Value331-108-121
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name NGM Biopharmaceuticals, Inc.
Country United States
Employees 186
CEO David J. Woodhouse

Stock Information

Ticker Symbol NGM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NGM


NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.